11.13.20
6 min. Read

Scoop: Amwell in talks to buy Omada

Issue 078

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last Friday I wrote about ICER's blistering report on Pear, Orexo's DTC move with its substance use disorder DTx, plus feedback for CMS on its plans for reimbursing breakthrough devices.

And if you

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!
×

Full access to E&O's research and newsletters.

Get the subscribers-only newsletters + research reports + databases
$120M in secret health tech deals: Pearl Health, Amalgam Rx and more
1.23.23
5 min. Read
Florida Medicaid covers Pear. MedRhythms pivotal. Trials
1.20.23
6 min. Read
Akili layoffs, pipeline changes. DiGA price drop. Trials
1.13.23
7 min. Read
Big company benefits stack: T-Mobile
1.11.23
5 min. Read
Apple-Janssen Heartline study recruits 34K (not 150K). New DiGA.
1.06.23
5 min. Read
Trials. Omnibus excludes PDTs. ITC’s Apple Watch ban
12.23.22
6 min. Read
Six secret health tech deals
12.19.22
3 min. Read
New bill asks Medicaid to cover PDTs. More Apple-AliveCor.
12.16.22
7 min. Read
Big company benefits stack: Oracle
12.14.22
4 min. Read
New CPT applicants. ITC delays Apple-AliveCor one week.
12.09.22
7 min. Read
  • First
  • Previous
  • 1 of 29
  • Next
  • Last